The dissemination of general health and science information has long been a cornerstone of public health education, providing accessible knowledge on disease prevention, wellness, and the biological basis of health. This legacy, rooted in institutional missions to educate communities and support clinical care, established a broad framework for interpreting medical data and translating complex scientific findings into actionable guidance. Within this context, the systematic classification of health conditions—such as the standardized coding used to document digestive motility disorders—represents a critical tool for clinical communication and epidemiological tracking. These coding systems enable consistent documentation across healthcare settings, facilitating research and quality improvement initiatives that benefit patient populations at large. (https://www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched/cpt-coding)
While general health education has traditionally focused on lifestyle and clinical care, attention must also shift toward the occupational environment as a distinct and often underappreciated source of exposure. Workers in pharmaceutical manufacturing, laboratory research, and healthcare delivery may come into contact with active substances or chemical agents that, under specific conditions, could influence physiological function. This transition from general health education to occupational exposure concern does not presuppose causation but rather highlights the need for vigilance in monitoring and documenting potential adverse effects within workforce populations. By leveraging established coding and reporting mechanisms, occupational health professionals can better identify patterns that warrant further investigation, thereby extending the legacy of health information into the realm of workplace safety and preventive medicine.
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Clinically, patients present with postprandial fullness, early satiety, nausea, vomiting, bloating, and upper abdominal pain. Diagnosis is typically confirmed through gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach; delayed emptying at 2 and 4 hours is diagnostic. Other diagnostic modalities include wireless motility capsule testing and breath tests using stable isotopes. The clinical presentation of gastroparesis overlaps with functional dyspepsia, necessitating careful exclusion of structural lesions via endoscopy or imaging. Severity is graded based on symptom burden and response to therapy, ranging from mild (manageable with dietary modification) to severe (refractory symptoms requiring nutritional support or surgical intervention). The condition can lead to complications such as malnutrition, electrolyte imbalances, and bezoar formation, which may require hospitalization.
Several pharmaceutical classes are associated with drug-induced gastroparesis. Glucagon-like peptide-1 (GLP-1) receptor agonists, used for type 2 diabetes and obesity, slow gastric emptying as a primary pharmacologic effect. This mechanism is dose-dependent and may persist with chronic use. Other agents include opioids, which inhibit gastric motility via mu-opioid receptors in the enteric nervous system; anticholinergics, which block muscarinic receptors and reduce gastrointestinal smooth muscle contraction; and calcium channel blockers, which interfere with smooth muscle calcium influx. Additionally, tricyclic antidepressants, dopamine agonists, and progesterone analogs have been implicated. The onset of symptoms can vary from days to months after drug initiation, depending on the agent and individual susceptibility. In some cases, the adverse effect is reversible upon drug discontinuation, but prolonged exposure may lead to irreversible myenteric plexus damage. The reported incidence of drug-induced gastroparesis is not well quantified, but it is recognized as a clinically significant adverse event, particularly in vulnerable populations such as the elderly or those with pre-existing autonomic neuropathy.
The mechanistic pathways underlying pharmaceutical-induced gastroparesis involve disruption of the neural and muscular components of gastric motility. The stomach’s pacemaker cells, the interstitial cells of Cajal, generate slow waves that coordinate smooth muscle contraction. Drugs may impair this system by altering neurotransmitter release, receptor binding, or intracellular signaling. For example, GLP-1 receptor agonists activate receptors on vagal afferent neurons and gastric smooth muscle, leading to reduced antral contractility and increased pyloric tone. Opioids bind to receptors in the myenteric plexus, inhibiting acetylcholine release and thus decreasing propulsive contractions. Anticholinergics directly block muscarinic M2 and M3 receptors on smooth muscle, reducing contractile force. Additionally, some drugs may induce oxidative stress or mitochondrial dysfunction in enteric neurons, leading to apoptosis and neuropathy. Chronic exposure can result in structural remodeling, including fibrosis of the muscularis propria and loss of interstitial cells of Cajal, which may explain why some patients do not recover after drug cessation. The vagus nerve, which provides parasympathetic input to the stomach, is also a target; drugs that impair vagal signaling can mimic the effects of surgical vagotomy.
Regulatory safety communications have highlighted the risk of gastroparesis associated with certain pharmaceuticals. For instance, the U.S. Food and Drug Administration (FDA) has issued warnings regarding GLP-1 receptor agonists, noting reports of severe gastrointestinal adverse events, including gastroparesis, in postmarketing surveillance (https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers). These communications advise healthcare professionals to monitor patients for symptoms of delayed gastric emptying, particularly when initiating or escalating doses. The prescribing information for these agents includes warnings about gastrointestinal effects, and patients are counseled to report persistent nausea, vomiting, or abdominal pain. For opioids, safety communications emphasize the risk of delayed gastric emptying and recommend dose adjustments or alternative therapies in patients with pre-existing motility disorders. The clinical interpretation for affected patients involves recognizing that symptoms may be drug-related, prompting a risk-benefit assessment. In some cases, switching to an alternative agent with a lower risk profile is warranted. Documentation of the adverse effect in the medical record should include the specific drug, dose, duration of exposure, and temporal relationship to symptom onset. This information is critical for accurate coding and for informing future prescribing decisions.
For affected patients, the appropriate ICD-10-CM code for gastroparesis is K31.84. This code is used to report the diagnosis of gastroparesis, regardless of etiology. When the gastroparesis is drug-induced, an additional code from the T36-T50 range should be assigned to identify the specific pharmaceutical agent and the adverse effect. For example, poisoning by, adverse effect of, and underdosing of antidiabetic drugs is coded as T38.3X5, with the fifth or sixth character indicating the specific drug. The adverse effect should be sequenced as the primary diagnosis, followed by the manifestation code K31.84. For opioids, the code is T40.6X5 (adverse effect of narcotics). For anticholinergics, the code is T44.3X5 (adverse effect of other parasympatholytics). The external cause code is not required for adverse effects, as the drug itself is the cause. In the outpatient setting, the coder should verify that the clinician has documented the drug-adverse effect relationship. For inpatient encounters, the same coding principles apply, with the adverse effect as the principal diagnosis if it is the reason for admission. Additionally, if the patient requires procedures such as gastric emptying scintigraphy (CPT 91022) or esophagogastroduodenoscopy (CPT 43235), these should be reported separately. For patients with refractory symptoms, codes for malnutrition (E43-E46) or electrolyte imbalance (E87) may be added if documented. (https://www.icd10data.com/ICD10CM/Codes/K00-K95/K30-K38/K31-/K31.84)
The timeline between pharmaceutical exposure and the onset of gastroparesis varies by drug class. For GLP-1 receptor agonists, delayed gastric emptying can occur within the first few weeks of treatment, with symptoms often emerging after dose escalation. In clinical trials, gastrointestinal adverse events were most frequent during the initial titration period. For opioids, the effect on gastric emptying is acute, occurring within hours of administration, but chronic use can lead to persistent symptoms. Anticholinergics similarly produce rapid effects, though tolerance may develop. In some cases, the onset is insidious, with patients attributing symptoms to other causes, delaying diagnosis. The resolution of symptoms after drug discontinuation also varies; some patients improve within days, while others may take weeks or months. In cases where irreversible neuropathy has occurred, symptoms may persist indefinitely. Documenting the temporal relationship is essential for establishing causality and for coding accuracy. Clinicians should record the start date of the drug, the onset date of symptoms, and any changes in symptoms after dose adjustment or cessation. This information supports the assignment of the adverse effect code and facilitates appropriate management.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
| Field | Value |
|---|---|
| Code | K31.84 |
| Description | Gastroparesis |
| Category | Diseases of the digestive system (K00-K95) |
| Billable | Yes |
| Adverse effect code | T36-T50 (e.g., T38.3X5 for antidiabetics) |
| Sequencing | Adverse effect first, then K31.84 |
| Excludes | Functional dyspepsia (K30) |
| Notes | Use additional code for drug-induced if applicable |
The ICD-10-CM code for gastroparesis is K31.84. This code is used to report the diagnosis regardless of etiology. When drug-induced, an additional code from the T36-T50 range should be assigned to identify the specific pharmaceutical agent and the adverse effect.
For drug-induced gastroparesis, the adverse effect code (e.g., T38.3X5 for antidiabetic drugs) is sequenced first, followed by the manifestation code K31.84. The specific drug class determines the T-code, such as T40.6X5 for opioids and T44.3X5 for anticholinergics.
Common pharmaceutical causes include GLP-1 receptor agonists, opioids, anticholinergics, calcium channel blockers, tricyclic antidepressants, dopamine agonists, and progesterone analogs. These agents can impair gastric motility through various mechanisms.
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.